Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the safety, tolerability, and efficacy of NGM282 in patients with nonalcoholic steatohepatitis.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
NGM Biopharmaceuticals, Inc
Collaborators
NCT06318169 · Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
NCT05842512 · Nonalcoholic Steatohepatitis (NASH)
NCT06216041 · Nonalcoholic Steatohepatitis (NASH)
NCT04104321 · Nonalcoholic Steatohepatitis (NASH)
NCT04616014 · Nonalcoholic Steatohepatitis (NASH)
NGM Clinical Study Site 922
Chandler, Arizona
NGM Clinical Study Site 923
Tucson, Arizona
NGM Clinical Study Site 924
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions